BRIDGEBIO PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates BridgeBio Pharma, Inc. - BBIO

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”). KSF is investigating whether BridgeBio’s board of directors breached their fiduciary duties in connection with a transaction (the “Transaction”) whereby BridgeBio transferred certain of its early-stage clinical and pre-clinical stage drugs to a new joint venture. KSF is investigating whether the Transaction was fair to BridgeBio and its public stockholders.

If you hold shares of BridgeBio stock (Nasdaq: BBIO), we urge you to contact KSF to discuss your legal rights, without obligation or cost to you, by calling KSF toll-free at 1-833-938-0905, or by e-mailing KSF Managing Partner, Lewis Kahn, at lewis.kahn@ksfcounsel.com.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana and New Jersey.

To learn more about KSF, you may visit ksfcounsel.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240830921462/en/